InsidersTradesSigma
Follow the RHYTHM PHARMACEUTICALS INC stock price and the full management transaction log of the company, a publicly traded company based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €7.4bn. The latest transaction was disclosed on 13 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: JOSEPH J SHULMAN. The full history is openly available.
Analysts rate RHYTHM PHARMACEUTICALS INC Buy (bullish), based on 16 analysts. Average price target: US$140.19.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
2 of 2 declarations
RHYTHM PHARMACEUTICALS INC is a biopharmaceutical company focused on developing treatments for central nervous system disorders. It is listed on NASDAQ under the ticker RYTM.